Oxford BioMedica PLC provided revenue guidance for the rest of 2013 and 2014. During the rest of 2013 and 2014, the company reported that revenues are expected to be generated from intellectual property, development and manufacturing alliances and a potential significant option fee that may arise should Sanofi choose to exercise its option over RetinoStat(Registered).